Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29064997 | 0.79 | MRGPRX4 (0.48) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL3584022 | 0.78 | MRGPRX4 (0.45) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL836468 | 0.76 | MRGPRX4 (0.51) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL261525 | 0.73 | ALDH1A1 (0.66) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL7013256 | 0.70 | ALDH1A1 (0.46) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL262044 | 0.70 | HPGD (0.56) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL17586412 | 0.69 | DAO (0.48) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL9684214 | 0.69 | DAO (0.44) | MRGPRX4TP53PKMLIG1DAO | |
| SCHEMBL3272099 | 0.69 | RXRA (0.53) | ALDH1A1NR4A2 | |
| SCHEMBL17686819 | 0.69 | NPC1 (0.56) | MRGPRX4ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123651-A1 | CONDENSED PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | MRGPRX4 637/4885TP53 328/4885PKM 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.